(PR-inside.com) FOR NON-US MEDIA ONLY Patients with metastatic colorectal cancer (mCRC) receiving BIBF 1120* as first-line treatment in combination with mFOLFOX6 showed a median progression-free survival of 10.6 months which was equivalent to bevacizumab plus mFOLFOX6 in a randomised two arm phase II study enrolling a total of 126 patients. Importantly, only 34.1% of those patients taking BIBF 1120* experienced any kind of serious adverse events, versus 53.7% of those taking bevacizumab.More detailed results from the trial are.- The objective response rate (ORR), a measure of tumour shrinkage, was 61.2% in the BIBF 1120* arm and 53.7% in the bevacizumab ..
More...
More...